Treatment

Phase IIb ELAD trial of liraglutide in mild-moderate Alzheimer’s disease

The future of gene targeting in treating Parkinson’s disease

The potential of lecanemab for the treatment of early Alzheimer’s disease

Donanemab: breakthrough therapy designation based on TRAILBLAZER data

Aducanumab: what’s the latest?

Lecanemab for the treatment of early Alzheimer’s disease: the story so far

Lecanemab: Phase II open-label extension results

Major ongoing clinical trials in AD: aducanumab, donanemab & lecanemab

Phase III AHEAD 3-45 trial of lecanemab for preclinical Alzheimer’s disease

Phase III ADMET2 trial of methylphenidate for apathy in Alzheimer’s Disease

Increasing eIF2a phosphorylation to boost protein quality control in neurodegenerative disease

Highlights from AAIC: Targeting the immune response to treat AD

Manipulating protein quality control systems in neurodegenerative diseases: next steps

Emerging concepts: boosting protein quality control to treat neurodegenerative disease

Using antibodies and intrabodies to target pathogenic TDP-43 in ALS

Protecting cells from misfolding stress to improve cell survival in neurodegenerative disease